Co-Diagnostics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $622.5K | $3.9M | $6.8M | $34.2M | $97.9M | $74.6M | $215.0K | $39.9K |
| Cost of Revenue | $222.4K | $999.1K | $4.2M | $5.5M | $11.6M | $16.6M | $112.4K | $9.4K |
| Gross Profit | $400.1K | $2.9M | $2.6M | $28.7M | $86.3M | $58.0M | $102.5K | $30.5K |
| Gross Margin | 64.3% | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% | 47.7% | 76.5% |
| Operating Expenses | ||||||||
| Research & Development | $19.1M | $21.0M | $23.0M | $17.4M | $15.0M | $3.2M | $1.4M | $1.4M |
| SG&A Expense | $9.1M | $16.2M | $14.3M | $14.3M | $11.6M | $8.3M | $3.5M | $3.6M |
| Operating Income | $-50.2M | $-40.1M | $-42.7M | $-27.0M | $46.1M | $41.7M | $-5.9M | $-6.1M |
| Operating Margin | -8,058.8% | -1,023.7% | -626.9% | -78.8% | 47.1% | 55.9% | -2,741.6% | -15,328.6% |
| Interest Expense | — | — | — | — | — | — | $106.4K | $71.0K |
| Pretax Income | $-48.5M | $-37.6M | $-38.1M | $-18.8M | $45.6M | $42.6M | $-6.2M | $-6.3M |
| Income Tax Expense | $-1.6M | $57.4K | $-2.8M | $-4.6M | $9.0M | $90.5K | — | — |
| Net Income | $-46.9M | $-37.6M | $-35.3M | $-14.2M | $36.7M | $42.5M | $-6.2M | $-6.3M |
| Net Margin | -7,533.6% | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% | -2,882.0% | -15,714.3% |
| EPS (Basic) | $-35.25 | $-37.22 | $-1.20 | $-0.45 | $1.27 | $1.59 | $-0.37 | $-0.50 |
| EPS (Diluted) | $-35.25 | $-37.22 | $-1.20 | $-0.45 | $1.23 | $1.52 | $-0.37 | $-0.50 |
| Shares Outstanding (Basic) | 1.3M | 1.0M | 29.3M | 31.5M | 28.9M | 26.7M | 16.8M | 12.9M |
| Shares Outstanding (Diluted) | 1.3M | 1.0M | 29.3M | 31.5M | 29.9M | 28.0M | 16.8M | 12.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |